A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer

被引：5

作者：

Lee, Jeeyun ^{[1
]}

Shin, Sang Joon ^{[2
]}

Chung, Ik Joo ^{[3
]}

Kim, Tae Won ^{[4
]}

Chun, Hoo-Geun ^{[5
]}

Shin, Dong Bok ^{[6
]}

Kim, Yeul Hong ^{[7
]}

Song, Hong Suk ^{[8
]}

Han, Sae-Won ^{[9
]}

Kim, Jong Gwang ^{[10
]}

Kim, Sun Young ^{[11
]}

Choi, Young Jin ^{[12
]}

Chung, Hyun Cheol ^{[2
,13
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[2] Yonsei Univ, Coll Med, Severance Hosp, Div Hematol Oncol,Dept Med, Seoul, South Korea

[3] Chonnam Natl Univ, Hwasun Hosp, Dept Med, Div Hematol Oncol, Kwangju, South Korea

[4] Asan Med Ctr, Div Hematol Oncol, Dept Med, Seoul, South Korea

[5] Seoul St Marys Hosp, Div Hematol Oncol, Dept Med, Seoul, South Korea

[6] Gachon Univ, Gil Hosp, Dept Med, Div Hematol Oncol, Inchon, South Korea

[7] Korea Univ, Anam Hosp, Dept Med, Div Hematol Oncol, Seoul, South Korea

[8] Keimyung Univ, Dongsan Hosp, Dept Med, Div Hematol Oncol, Seoul, South Korea

[9] Seoul Natl Univ Hosp, Dept Med, Div Hematol Oncol, Seoul 110744, South Korea

[10] Kyungpook Natl Univ Hosp, Div Hematol Oncol, Dept Med, Taegu, South Korea

[11] Natl Canc Ctr, Div Hematol Oncol, Dept Med, Goyang Si, South Korea

[12] Pusan Natl Univ Hosp, Div Hematol Oncol, Dept Med, Pusan, South Korea

[13] Yonsei Univ, Severance Hosp, Dept Med Oncol, Seoul 120752, South Korea

来源：

INVESTIGATIONAL NEW DRUGS | 2014年 / 32卷 / 03期

关键词：

Colorectal cancer; Chemotherapy; TSU-68; 1ST-LINE TREATMENT; PLUS IRINOTECAN; ORAL S-1; BEVACIZUMAB; FLUOROURACIL; LEUCOVORIN; EFFICACY; THERAPY; FOLFIRI; MARKERS;

D O I：

10.1007/s10637-014-0075-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths worldwide. The combination of oxaliplatin-based treatments (oxaliplatin plus infusional 5-fluorouracil and leucovorin [FOLFOX] or oxaliplatin plus capecitabine [CapeOX]) and bevacizumab is a standard chemotherapy regimen for metastatic CRC (mCRC). However, several clinical studies that tested S-1 plus oxaliplatin (SOX) indicate that SOX is also a treatment option for mCRC. TSU-68 is an oral compound that inhibits vascular endothelial growth factor receptor and platelet-derived growth factor receptor. The recommended dose of TSU-68 + SOX was previously determined in a phase I study of mCRC patients. The goal of this trial was to evaluate the efficacy of TSU-68 in combination with SOX. Methods This open-label multicenter randomized phase II trial was performed in Korea. Treatment-naive mCRC patients with a performance status of 0 or 1 were randomized in a 1:1 ratio to receive either TSU-68 + SOX or SOX alone. The primary endpoint was progression-free survival (PFS). Results A total of 105 patients (TSU-68 + SOX, 52 patients; SOX alone, 53 patients) were randomized. The median PFS was 7.0 months in the TSU-68 + SOX group (hazard ratio [HR], 1.057) and 7.2 months in the SOX group (p = 0.8401). The most frequent grade 3 and 4 adverse events were thrombocytopenia (9.6 % [TSU-68 + SOX] vs. 26.4 % [SOX]), neutropenia (13.5 % [TSU-68 + SOX] vs. 15.1 % [SOX]), and anemia (3.8 % [TSU-68 + SOX] vs. 13.2 % [SOX]). We observed a difference between the 2 groups for all grades of anemia (15.4 % [TSU-68 + SOX] vs. 32.1 % [SOX]), diarrhea (30.8 % [TSU-68 + SOX] vs. 47.2 % [SOX]), vomiting (50.0 % [TSU-68 + SOX] vs. 26.4 % [SOX]), and chromaturia (23.1 % [TSU-68 + SOX] vs. 0.0 % [SOX]). Analysis using a Cox proportional hazard model showed that baseline interleukin 6 (IL-6) levels were associated with a survival benefit of TSU-68 (p = 0.012). Conclusion TSU-68 + SOX had a favorable safety profile. However, TSU-68 did not have a synergistic effect on the efficacy of SOX. The baseline serum IL-6 level could be a prognostic factor for TSU-68 efficacy.

引用

页码：561 / 568

页数：8

共 50 条

[41] Impact of Chemotherapy with S-1 and Oxaliplatin (SOX) in Combination with Molecular-targeting Agents on Colorectal Liver Metastases [J].

Watanabe, Kazuhiro ;

Kawahara, Hidejiro ;

Enomoto, Hiroya ;

Toyama, Yoichi ;

Akiba, Tadashi ;

Yanaga, Katsuhiko .

ANTICANCER RESEARCH, 2013, 33 (09) :3941-3946

[42] A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer [J].

Naminatsu Takahara ;

Hiroyuki Isayama ;

Yousuke Nakai ;

Takashi Sasaki ;

Tsuyoshi Hamada ;

Rie Uchino ;

Suguru Mizuno ;

Koji Miyabayashi ;

Hirofumi Kogure ;

Natsuyo Yamamoto ;

Naoki Sasahira ;

Kenji Hirano ;

Hideaki Ijichi ;

Keisuke Tateishi ;

Minoru Tada ;

Kazuhiko Koike .

Cancer Chemotherapy and Pharmacology, 2013, 72 :985-990

[43] A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial) [J].

Matsusaka, Satoshi ;

Ishihara, Soichiro ;

Kondo, Keisaku ;

Horie, Hisanaga ;

Uehara, Keisuke ;

Oguchi, Masahiko ;

Murofushi, Keiko ;

Ueno, Masashi ;

Mizunuma, Nobuyuki ;

Shimbo, Taiju ;

Kato, Daiki ;

Okuda, Junji ;

Hashiguchi, Yojiro ;

Nakazawa, Masanori ;

Sunami, Eiji ;

Kawai, Kazushige ;

Yamashita, Hideomi ;

Okada, Tohru ;

Ishikawa, Yuichi ;

Nakajima, Toshifusa ;

Watanabe, Toshiaki .

RADIOTHERAPY AND ONCOLOGY, 2015, 116 (02) :209-213

[44] A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer [J].

Sun Young Kim ;

Yong Sang Hong ;

Byung Chang Kim ;

Ji Won Park ;

Hyo Seong Choi ;

Seung-Yong Jeong ;

Dae Yong Kim ;

Chang Won Hong ;

Dae Kyung Sohn ;

Kyung Hae Jung .

Investigational New Drugs, 2009, 27 :269-274

[45] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study) [J].

Dai, Yu-Hong ;

Yu, Xiong-Jie ;

Xu, Hui-Ting ;

Zhuang, Liang ;

Zhang, Ming-Sheng ;

Zou, Yan-Mei ;

Fu, Qiang ;

Qiu, Hong ;

Yuan, Xiang-Lin .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14

[46] Combination therapy of S-1 and CDDP for patients with colorectal cancer [J].

Kazumi Uchida ;

Kazuhiko Hayashi ;

Hidekazu Kuramochi ;

Go Nakajima ;

Yuji Inoue ;

Masakazu Yamamoto .

Journal of Cancer Research and Clinical Oncology, 2007, 133 :841-846

[47] Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen [J].

Tanioka, Hiroaki ;

Shimada, Ken ;

Tsuji, Akihito ;

Kochi, Mitsugu ;

Kim, Ho Min ;

Takahashi, Takao ;

Denda, Tadamichi ;

Takagane, Akinori ;

Watanabe, Takanori ;

Kotaka, Masahito ;

Nakamura, Masato ;

Sunakawa, Y. U. ;

Takeuchi, Masahiro ;

Ichikawa, Wataru ;

Fujii, Masashi .

ANTICANCER RESEARCH, 2022, 42 (05) :2675-2681

[48] Combination therapy of S-1 and CDDP for patients with colorectal cancer [J].

Uchida, Kazumi ;

Hayashi, Kazuhiko ;

Kuramochi, Hidekazu ;

Nakajima, Go ;

Inoue, Yuji ;

Yamamoto, Masakazu .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (11) :841-846

[49] Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer [J].

Koizumi, W. ;

Boku, N. ;

Yamaguchi, K. ;

Miyata, Y. ;

Sawaki, A. ;

Kato, T. ;

Toh, Y. ;

Hyodo, I. ;

Nishina, T. ;

Furuhata, T. ;

Miyashita, K. ;

Okada, Y. .

ANNALS OF ONCOLOGY, 2010, 21 (04) :766-771

[50] Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001) [J].

Ozawa, Mayumi ;

Watanabe, Jun ;

Ishibe, Atsushi ;

Goto, Koki ;

Fujii, Yoshiro ;

Nakagawa, Kazuya ;

Suwa, Yusuke ;

Suwa, Hirokazu ;

Masui, Hidenobu ;

Sugita, Mitsutaka ;

Mochizuki, Yasuhisa ;

Yamagishi, Shigeru ;

Hasegawa, Seiji ;

Homma, Yuki ;

Momiyama, Masashi ;

Kumamoto, Takafumi ;

Matsuyama, Ryusei ;

Takeda, Kazuhisa ;

Taguri, Masataka ;

Endo, Itaru .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (06) :565-573

← 1 2 3 4 5 →